Cathie Wood, chief executive of Ark Investment Management, unloaded 175,491 shares of Exact Sciences on Jan. 23, possibly to take advantage of the stock’s recent gains. Exact Sciences is the largest holding in Wood’s flagship Ark Innovation ETF.
Exact Sciences, a medical diagnostics company, has lost 11% in its stock price over the past year, but has climbed +119% since Oct. 14 on the back of strong earnings and the overall market rally.
This unloading comes a few weeks after Wood’s team predicted that Exact Sciences stock could nearly triple in value by the year 2027. On Jan. 5, Ark Invest said, “In our base case, shares of Exact Sciences could compound at an average annual rate of 25%, reaching $140 by 2027.”
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
a developer of proprietary technologies for the detection of cancer
Industry MedicalSpecialties